Search results
Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook
Zacks via Yahoo Finance· 8 months agoNovartis NVS completed the spin-off of its generic and biosimilar unit, Sandoz, following which...
The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie
Zacks via Yahoo Finance· 2 years agoFor Immediate Release Chicago, IL – July 25, 2022 – Zacks.com announces the list of stocks featured...
Novartis, Moderna Partner Agrees To Merge With Beleaguered Sesen Bio
Benzinga via Yahoo Finance· 2 years agoSesen Bio Inc (NASDAQ: SESN) and privately held Carisma Therapeutics Inc have entered into a merger...
Savvy Investors Plow Money Into These 10 Stocks And One IPO
Investor's Business Daily· 1 year agoMicrosoft, Paccar, Broadcom and Salesforce top this month's list of new buys by the best mutual...
Hot Biotech Play Breaks Out Into By Range
Investor's Business Daily· 5 months agoA mix of choppy or nonexistent earnings alongside the promise of game-changing breakthroughs make biotech stocks a challenge for investors. The SPDR S&P...
Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study
Zacks via Yahoo Finance· 1 year agoMerck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ)...
Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today
Zacks via Yahoo Finance· 1 year agoHow much a stock's price changes over time is a significant driver for most investors. Not only can...
Immunome (IMNM) Surges on Merger Agreement With Morphimmune
Zacks via Yahoo Finance· 11 months agoImmunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will...
Weekly Upgrades and Downgrades
InvestorPlace via Yahoo Finance· 1 year agoDuring these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking...
Cullinan changes name, pivots to autoimmune disease
BioPharma Dive via Yahoo Finance· 1 month agoThe biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other...
